MedTrace Logo

Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

NCT01723202 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-08-24

Study results available
· View outcomes & findings →

Summary

This randomized phase II trial studies how well dabrafenib works with or without trametinib in treating patients with recurrent thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether dabrafenib is more effective when given with or without trametinib in treating thyroid cancer

Conditions

  • Follicular Thyroid Cancer
  • Insular Thyroid Cancer
  • Papillary Thyroid Cancer
  • Recurrent Thyroid Cancer

Interventions

DRUG

dabrafenib

150 mg orally twice daily given orally

DRUG

trametinib

150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally

Sponsors & Collaborators

Principal Investigators

  • Bhavana Konda, MD · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-07
Primary Completion
2022-04-15
Completion
2022-04-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01723202 on ClinicalTrials.gov